Retinal Pharmacotherapy

Retinal Pharmacotherapy

By Quan Dong Nguyen, MD. MSc, Associate Professor of Ophthalmology, Diseases of the Retina and Vitreous, and Uveitis, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Eduardo Buchele Rodrigues, MD, Department of Ophthalmology, Vision Institute, Federal University of São Paulo, São Paulo, Brazil ; Michel Eid Farah, MD, Professor of Ophthalmology and Vice-chairman, Retina and Vitreous Department, Vision Institute Federal University of São Paulo, São Paulo, Brazil and William F Mieler, MD, Professor and Vice-Chairman, Department of Ophthalmology & Visual Sciences, University of Illinois at Chicago, IL, USA


1 Evolving Knowledge in Pharmacologic
Treatments

Section 1: Basic Sciences in Retina

2 Retinal Anatomy and Pathology

3 Retinal Biochemistry, Physiology and
Cell Biology

4 Ocular Angiogenesis: Vascular Endothelial
Growth Factor and Other Factors

5 Ocular Immunity and Inflammation

6 Complement Activation and Inhibition in
Retinal Disease

7 Genetics of Retinal Disease

Section 2: Animal Models and Routes for
Retinal Drug Delivery

8 Vitamins and Supplements for Age-Related
Macular Degeneration

9 Ocular Pharmacokinetic, Drug Bioavailability and Intraocular Drug Delivery Systems

0 Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections and Vitrectomy

11 Routes for Drug Delivery: Topical, Transscleral, Suprachoroidal, and Intravitreal
Gas-Phase Nanoparticles

12 Routes for Drug Delivery: Sustained-Release
Devices

13 Microspheres and Nanotechnology for
Drug Delivery

14 Thermo-sensitive Hydrogels

15 Retina and Ocular Toxicity to Ocular Application
of Drugs

16 Retinal Toxicity of Systemic and Topical
Medications

Section 3: Retinal Diseases Amenable to Pharmacotherapy

17 Non-neovascular Age-Related Macular
Degeneration

18 Neovascular Age-Related Macular Degeneration

19 Diabetic Retinopathy and Diabetic
Macular Edema

20 Retinal Vein Occlusion

21 Retinal Detachment and Proliferative
Vitreoretinopathy

22 Posterior Uveitis

23 Choroidal Neovascularization Secondary
to Inflammation, Infection, and Myopia

24 Ocular Infection: Endophthalmitis

25 Retinopathy of Prematurity

26 Idiopathic Macular Telangiectasia

27 Neovascular Glaucoma

28 Retinal Hereditary and Degenerative /
Dystrophic Diseases (non-AMD)

Section 4: Drugs and Mechanisms in
Retinal Diseases

29 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
in the Treatment of Retinal Diseases

30 Corticosteroids: Triamcinolone, Dexamethasone, Fluocinolone, and Others

31 Anecortave Acetate

32 Therapeutic Monoclonal Antibodies and
Fragments: Bevacizumab

33 Therapeutic Monoclonal Antibodies and
Fragments: Ranibizumab

34 Pathophysiology of Vascular Endothelial Growth
Factor and Other Angiogenic Molecules

35 Biologic Therapies: Infliximab, Adalimumab,
Etanercept, Daclizumab, and Others

36 Immunomodulatory Therapy in Uveitis

37 Fusion Proteins: VEGF-Trap

38 Aptamers and Intramers: Pegaptanib

39 Protein Kinase C Inhibitor: Ruboxistaurin

40 Small-Interference RNA Technology: SIRNA 027, Bevasiranib, and REDD14NP

41 Ocular Gene Therapy

42 Neuroprotection and Retinal Diseases

43 Photosensitizers and Photodynamic Therapy:
Verteporfin

44 Chemotherapy for Malignant Intraocular Tumors

45 Antibiotics

Section 5: Pharmacotherapy and Surgery

46 Rheotherapy (Rheopheresis; Therapeutical
Apheresis)

47 Enzymatic Vitrectomy and Pharmacologic
Vitreodynamics

48 The Use of Vital Dyes during Vitreoretinal Surgery - Chromovitrectomy

49 Epimacular and External Radiotherapy

50 Current Status of Human Retinal Pigment
Epithelial Transplantation

Section 6: The Last Words

51 Off-Label Drugs and the Impact of the Food and
Drug Administration in the Treatment of
Retinal Disease

52 Value-Based Medicine and Pharmacoeconomics

53 Future Perspectives: Agents on the Horizon